← Back

Hebei Changshan Biochem Pharma

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is a Chinese company that researches, develops, produces, markets, and sells drugs for cardiovascular, cerebrovascular, diabetes, and cancer indications. Its product portfolio includes heparin sodium, calcium, and lithium, heparinoid, low molecular weight heparins, sodium hyaluronate, dalteparin sodium, enoxaparin sodium, nadroparin calcium, heparin sodium injections, sildenafil citrate tablets, and albenatide. The company also provides technology development, consulting, transfer services, investment and management of medical service projects, wholesale and retail of pharmaceuticals, and diagnostic services. Founded in 1992 and based in Shijiazhuang, China, it exports to the United States, Germany, France, Italy, Spain, South Korea, Japan, Russia, India, the Philippines, and other countries.

Price · split & dividend adjusted
News & notes moving 300255.CS
300255.CS

Changshan Pharmaceutical General Manager Gao Xiaodong Resigns, Remains Chairman; Chang Yanlu Assumes Duties

Hebei Changshan Biochemical Pharmaceutical announced that Chairman and General Manager Gao Xiaodong has resigned from the general manager position due to work adjustments. He will continue to serve as Chairman and Chairman of the Strategy Committee. His original term was set to run until December 26, 2027. The resignation report took effect upon delivery to the board of directors. As of the announcement date, he holds 1,530,000 shares in the company. To ensure daily operations and management, the company's sixth board of directors approved at its ninth meeting to authorize Deputy General Manager Chang Yanlu to perform the duties of general manager, effective from the date of board approval until a new general manager is appointed. Chang Yanlu was born in 1983, holds a postgraduate degree, and is a senior auditor, certified public accountant, and certified tax agent. He previously served as Financial Audit Director in the Audit Department of Shougang Group. He joined the company in August 2021 and has served as Deputy General Manager since December 2024. He does not hold company shares and has no related-party relationship with the controlling shareholder or shareholders holding more than 5 percent of shares.
300255.CS
Jiemian·12dRead more →
300255.CS▼

Changshan Pharmaceutical reports net loss of 16.7618 million yuan in 2026 interim results

Changshan Pharmaceutical released its 2026 interim report, showing total operating revenue of 476 million yuan, down 3.21 percent year on year, and a net loss attributable to the parent company of 16.7618 million yuan. Net cash inflow from operating activities was 20.5939 million yuan, a sharp year-on-year decline of 88.11 percent. The company's asset-liability ratio was 74.46 percent, gross margin was 21.62 percent, return on equity was negative 1.41 percent, and diluted earnings per share was negative 0.02 yuan. The number of shareholders was 52,900, and the top ten shareholders held 37.97 percent of the total share capital.
300255.CS ▼
Jiemian·24dRead more →
300255.CS▲

Changshan Pharmaceutical's Dalteparin Sodium Injection Selected for the 12th National Drug Procurement

Hebei Changshan Biochemical Pharmaceutical announced that its product Dalteparin Sodium Injection has been selected for the 12th round of national centralized drug procurement. The selected specifications are 0.2 ml: 5000 IU and 0.3 ml: 7500 IU, with indications including acute deep vein thrombosis and anticoagulation for hemodialysis. The product achieved sales revenue of 119.94 million yuan in 2025, accounting for 13.71 percent of the company's total revenue for the year. The procurement cycle runs from the implementation date of the selection results until December 31, 2029. The company stated that if procurement contracts are subsequently signed and executed, it will help promote product sales, but there remains uncertainty regarding contract signing and the impact on future performance.
300255.CS ▲
Jiemian·47dRead more →
Biotech & Genomic Medicine▲

Changshan Pharmaceutical hits daily limit up with over 100,000 lots sealed on the board

Changshan Pharmaceutical surged 20% to hit its daily limit up during intraday trading, with over 100,000 lots sealed on the board. The pharmaceutical sector strengthened broadly, with innovative drug concepts standing out. Medici and Shouyao Holdings rose over 10%, while Harbin Pharmaceutical, Shuanglu Pharmaceutical, and Lifang Pharmaceutical also hit their daily limit up. Changshan Pharmaceutical recently stated that its abenatide remains in the CDE review pipeline, with supplementary data work progressing steadily, and that its nadroparin calcium injection and enoxaparin sodium injection have successfully renewed their tenders. On the industry front, the innovative drug and CXO sectors have delivered strong overall performance since 2025, with rapid growth continuing into the first quarter of 2026. Many innovative drug companies have already crossed or are about to cross their breakeven points, marking the sector's entry into an earnings boom. CITIC Securities noted that the fundamentals of China's innovative drug industry are steadily improving in the second half of 2026, driven by higher R&D quality, global value validation, and better profitability.
300255.CS ▲
Biotech & Genomic Medicine ▲
证券时报·71dRead more →
© 2026 MarketDXAsset